Translational cancer research最新文献

{"title":"Construction and validation of an EGFR-related risk signature identified <i>SHC1</i> as a prognostic biomarker for lung adenocarcinoma.","authors":"Hanqin Cao, Bohao Sun, Jing Wang, Shanshan Wu, Na Shi, Jing Zhang, Yichen Wu, Hao Wang","doi":"10.21037/tcr-24-1812","DOIUrl":"10.21037/tcr-24-1812","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) is a significant subtype of lung cancer, contributing to high mortality rates and posing substantial challenges to public health. This study aims to explore the significance of the epidermal growth factor receptor (EGFR)-related gene <i>SHC1</i> in the progression and prognosis of LUAD.</p><p><strong>Methods: </strong>Patient RNA sequencing (RNA-seq) and clinical data were acquired from The Cancer Genome Atlas (TCGA) database. Using the least absolute shrinkage and selection operator (LASSO) Cox regression, we then generated a multigene signature of EGFR signaling-related genes (ESRGs) for the prognostic prediction of LUAD. We investigated the relationship between <i>SHC1</i> gene expression and immune cell infiltration by employing single-sample gene set enrichment analysis (ssGSEA). The potential functional role of the <i>SHC1</i> gene was evaluated through GSEA. Additionally, the association between <i>SHC1</i> expression and clinical data was investigated. Immunohistochemistry was utilized to assess <i>SHC1</i> expression in 88 cases of invasive pulmonary adenocarcinoma.</p><p><strong>Results: </strong>Univariate Cox regression analysis identified that increased expression of <i>SHC1</i> correlated with poorer overall survival (OS). <i>SHC1</i> exhibited significantly elevated expression levels in LUAD tissues. Moreover, elevated levels of <i>SHC1</i> gene expression correlated strongly with advanced tumor (T), node (N), and metastasis (M) stages and were significantly associated with immune cell infiltration in LUAD. Furthermore, marked increases in <i>SHC1</i> protein expression were observed in patients diagnosed with invasive pulmonary adenocarcinoma.</p><p><strong>Conclusions: </strong>These findings suggest that <i>SHC1</i> plays a crucial oncogenic role in LUAD. Increased <i>SHC1</i> expression in LUAD was associated with disease progression, an unfavorable prognosis, and dysregulated immune cell infiltration.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4331-4347"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A nine-gene signature with potential targets for predicting the prognosis of patients with esophageal cancer.","authors":"Mengfei Sun, Yandi Ma, Fuqiang Zhou, Quansheng Xiang, Shangfeng He, Jie Yu, Wenjie Wang, Jingwen Qi, Yang Wang, Qi Sun, Hui Li, Yunzhao Chen, Xiaobin Cui","doi":"10.21037/tcr-2025-146","DOIUrl":"10.21037/tcr-2025-146","url":null,"abstract":"<p><strong>Background: </strong>The incidence of esophageal squamous cell carcinoma (ESCC) is high and the prognosis is poor. It has become one of the important factors threatening the economic development and social stability of the region. The lack of effective early diagnostic biological indicators is the main reason for the late visit time and high mortality rate of clinical patients with ESCC. This study aims to investigate the role of long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) in predicting the prognosis and survival of patients with ESCC.</p><p><strong>Methods: </strong>Prognosis-related genes were studied by analyzing RNA sequencing data of ESCC in The Cancer Genome Atlas (TCGA) database, and they were divided into a training cohort (n=83) and a test cohort (n=76). A risk score model was constructed and prognosis-related markers were verified.</p><p><strong>Results: </strong>Nine prognosis-related genes (<i>RP11-51F16.1</i>, <i>FABP3</i>, <i>RP11-4K3-A.3</i>, <i>GNG12-AS1</i>, <i>RP11-2N1.2</i>, <i>PRICKLE2-AS1</i>, <i>KB-1254G8.1</i>, <i>AC132825.1</i>, and <i>RP11-294N21.3</i>) were screened out. Further construction of the risk score model revealed that the risk score was an independent prognostic factor. In addition, this study integrated prognostic markers and combined clinical features to develop a nomogram for predicting the overall survival (OS) rate for 1 to 3 years. Through quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) staining experiments, this study found that FABP3 was upregulated in ESCC, and patients with high expression of FABP3 had a shorter OS (P=0.04), and the upregulation of FABP3 was significantly correlated with the degree of differentiation of ESCC (P=0.04). Gene Set Enrichment Analysis (GSEA) indicated that the functions related to metabolism were mainly concentrated in the high-risk group. From a metabolic perspective, they played a role in regulating the tumorigenesis process. The analysis of changes in chemotherapy drug resistance found that the half maximal inhibitory concentration (IC₅₀) of 25 drugs was higher in the high-risk group, which confirmed that this feature played an important role in the prognosis and treatment of ESCC.</p><p><strong>Conclusions: </strong>This study identified a new set of characteristics of nine prognostic genes related to ESCC, which may provide ideas for prognosis prediction and new therapeutic methods for ESCC patients.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4305-4320"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maximal resection for malignant scalp tumors: is it valuable for long-term follow-up?","authors":"Yangbai Sun, Xuesi Liu, Qingrong Ye, Qinyuan Zhu, Chunmeng Wang, Wangjun Yan","doi":"10.21037/tcr-2024-2223","DOIUrl":"10.21037/tcr-2024-2223","url":null,"abstract":"<p><strong>Background: </strong>Balancing surgical margins with effective scalp reconstruction remains a contentious issue in scalp tumor resection. This study aimed to define optimal surgical and therapeutic strategies for tumor resection and subsequent reconstruction in this complex anatomical region.</p><p><strong>Methods: </strong>A retrospective study was conducted on 103 patients who underwent resection of malignant scalp tumors and reconstruction with flaps at Fudan University Shanghai Cancer Center. All patients received extended margin surgery followed by secondary treatment. Data collection included patient demographics, surgical details, defect characteristics, flap types, and treatment outcomes. The aesthetic outcome was assessed using a standardized five-point Likert scale, and follow-up data were collected through outpatient visits and telephone interviews until December 2023.</p><p><strong>Results: </strong>Among the 103 patients, 4 experienced local recurrence, and 10 developed lymph node metastases. Additionally, six patients had postoperative complications. Regarding aesthetic outcomes, one patient was dissatisfied, six were neutral, and the remaining patients were satisfied. Three representative clinical cases are described in detail. This study represents the largest single-center surgical cohort for malignant scalp tumors with complete long-term follow-up reported to date.</p><p><strong>Conclusions: </strong>This study proposes a novel concept: maximizing the tumor resection margin can effectively reduce local recurrence in patients, surpassing the traditional 2-cm margin. However, this approach does not significantly impact lymph node metastasis. Most patients undergoing scalp reconstruction with flaps achieved satisfactory aesthetic outcomes with minimal complications.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4024-4033"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: PA-MSHA exerts potent activity against cetuximab-resistant colorectal cancer through the miR-7-5p/Akt3/Wnt-β-catenin pathway.","authors":"","doi":"10.21037/tcr-2025b-6","DOIUrl":"10.21037/tcr-2025b-6","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/tcr-23-2211.].</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4476-4478"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and validation of a novel signature based on M2 macrophage co-expressed genes in bladder cancer.","authors":"Xinyu Xu, Minyu Yan, Zhiwen Xie, Yongqing Zhang, Lei Wu, Bimeng Zhang, Juntao Jiang","doi":"10.21037/tcr-24-2013","DOIUrl":"10.21037/tcr-24-2013","url":null,"abstract":"<p><strong>Background: </strong>Extensive evidence has demonstrated a robust association between high infiltration of M2 macrophages and the prognosis of bladder cancer (BLCA). Nevertheless, no comprehensive analysis of co-expressed M2 genes in BLCA has been reported. We would like to develop a prognostic model for BLCA using M2 co-expressed genes.</p><p><strong>Methods: </strong>Raw data and clinical characteristics were retrieved from public databases. We first used the \"cibersort\" package to determine the M2 macrophage infiltration coefficients of each BLCA sample in The Cancer Genome Atlas (TCGA). Subsequently, Pearson correlation was employed to screen co-expressed genes based on the coefficients. Least absolute shrinkage and selection operator (LASSO-COX) analysis was then employed to construct the prognostic gene signature, which was externally validated in the GSE13507 cohort. Further exploration of the signature involved tumor mutational burden (TMB) and drug sensitivity analyses. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was employed to validate the expression levels of the co-expressed genes.</p><p><strong>Results: </strong>We developed a signature using two co-expressed genes and utilized it to categorize samples into two groups. Patients in the low-risk group exhibited more satisfactory outcomes (P=0.008) and higher TMB (P=0.04). Additionally, the high-risk group exhibited a substantial discrepancy in immune subtypes compared to the low-risk group, as indicated by the significantly elevated levels of resting CD4 memory T cells, M0, and M2.</p><p><strong>Conclusions: </strong>We constructed a prognostic signature for BLCA based on two co-expressed genes. The performance of this signature was validated in both TCGA and GSE13507, indicating its potential usefulness in predicting the prognosis of BLCA and developing new therapeutic methods.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4194-4207"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and validation of hub genes for kidney renal clear cell carcinoma treated with metformin and everolimus combination therapy.","authors":"Shenbao He, Bin Zhang, Lili Zhang, Panfeng Shang, Zhongjin Yue","doi":"10.21037/tcr-2025-277","DOIUrl":"10.21037/tcr-2025-277","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Renal cell carcinoma (RCC) is a prevalent malignancy of the urinary system that presents significant health and economic burdens. Despite existing treatments such as surgery and targeted therapies, challenges remain due to suboptimal efficacy and high recurrence rates. Previous studies have indicated that metformin and everolimus individually exhibit inhibitory effects on RCC. However, their synergistic potential when combined has not been fully elucidated. Therefore, this paper identified the antiproliferative effect and the hub genes that undergo significant changes in 786-O cells when treated with the combination drugs and their underlying mechanisms to inform the search for kidney renal clear cell carcinoma (KIRC) therapeutic targets.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The effects of the combination of metformin and everolimus on 786-O cells viability, migration and invasion were investigated. Differentially expressed genes (DEGs) among different drug treatment groups were identified through ribonucleic acid (RNA) sequencing, raw data processing and differential expression analysis. The target genes were obtained by taking the intersection of different DEGs, and hub genes were identified by Maximal Clique Centrality (MCC) and Molecular Complex Detection (MCODE) algorithms, expression validation, and Kaplan-Meier (K-M) survival curve plotting. Subsequently, transcription factors (TFs) regulating the hub genes were identified and drug-hub gene interactions were explored through molecular docking. In addition, gene set enrichment analysis (GSEA) demonstrated hub gene-related biological functions and pathways, and gene set variation analysis (GSVA) explored differential pathways between different drug treatment groups. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify the expression difference of hub genes among four groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The combination of metformin and everolimus is more effective than monotherapy at inhibiting cell viability, migration, and invasion in 786-O cells. In total, 3,030 DEG1, 2,953 DEG2, 3,591 DEG3, 1,571 DEG4 and 4,064 DEG5 were identified, yielding five target genes. After MCC and MCODE algorithms, expression validation, and K-M survival curve plotting, target genes were all noted as hub genes (&lt;i&gt;SPC25&lt;/i&gt;, &lt;i&gt;NCAPH&lt;/i&gt;, &lt;i&gt;MCM10&lt;/i&gt;, &lt;i&gt;UHRF1&lt;/i&gt;, &lt;i&gt;SMC4&lt;/i&gt;). Eleven TFs regulated more than two hub genes, and the binding energy of metformin with &lt;i&gt;SPC25&lt;/i&gt; and everolimus with &lt;i&gt;SMC4&lt;/i&gt; was the lowest. Hub genes were negatively correlated with lysosome and positively associated with cell cycle, and the P13K/Akt/mTOR signaling pathway was significantly positively correlated with hub genes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Metformin and everolimus are synergistic in anticancer effects on RCC. Based on transcriptomic data, this study obtained five hub genes associated with everolimus and metformin combination therapy in ","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"3943-3960"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a quantitative genomic instability scoring system and a related competing endogenous RNA network in head and neck squamous cell carcinoma.","authors":"Wei Li, Fangqin Yu, Mingwei Wang, Xiguo Liu, Zhidan Mei","doi":"10.21037/tcr-24-1925","DOIUrl":"10.21037/tcr-24-1925","url":null,"abstract":"<p><strong>Background: </strong>Genomic instability (GI) is a hallmark of cancer and plays a crucial role in the progression of head and neck squamous cell carcinoma (HNSCC). This study aimed to quantitatively characterize GI features and construct a GI-related competing endogenous RNA (ceRNA) network in HNSCC.</p><p><strong>Methods: </strong>Weighted gene co-expression network analysis (WGCNA) and differential gene expression analysis were conducted to compare genomically stable and unstable HNSCC samples. Thirty-six hub GI-related genes (GIGs) were identified and used to categorize patients into distinct clusters through consensus clustering analysis. A GI scoring (GIS) system was then developed to assess its relationship with somatic mutations, tumor mutational burden (TMB), and differential gene expression, including genes such as <i>KRAS</i> and <i>TP53</i>. <i>In vitro</i> experiments were performed to explore the functional mechanism of the GI-associated ceRNA axis-RNF216P1/let-7b-5p/DUSP9. The expression levels of RNF216P1, let-7b-5p, and DUSP9 were also validated using clinical samples from a local hospital.</p><p><strong>Results: </strong>The identified 36 GIGs enabled the categorization of HNSCC patients into three distinct clusters, each exhibiting unique prognostic and immune profiles. The developed GIS system effectively distinguished between somatic mutations, TMB, and differential gene expression. Patients with higher GIS scores had better prognoses compared to those with lower scores. Additionally, GIS was positively correlated with overall immune cell infiltration and immune function, highlighting its potential in predicting responses to immunotherapy. The GI-associated ceRNA axis RNF216P1/let-7b-5p/DUSP9 was established, with The Cancer Genome Atlas (TCGA) analysis revealing upregulation of RNF216P1 and DUSP9 in tumor tissues, while let-7b-5p was downregulated. These expression trends were corroborated in clinical samples. <i>In vitro</i> experiments demonstrated that RNF216P1 functioned as a molecular sponge for let-7b-5p, leading to upregulation of DUSP9 and promoting oncogenesis in HNSCC.</p><p><strong>Conclusions: </strong>The GIS system is an effective biomarker for evaluating GI, prognosis, and immune features in HNSCC. The findings also clarify the functional mechanism of the GI-related ceRNA axis RNF216P1/let-7b-5p/DUSP9, providing valuable insights for future research and the development of therapeutic strategies for HNSCC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4115-4141"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study.","authors":"Martin Svaton, Miloslav Marel, Ondrej Venclicek, Juraj Kultan, Marketa Cernovska, Michal Hrnciarik, Jana Krejci, Karel Odrazka, Petr Domecky","doi":"10.21037/tcr-2024-2555","DOIUrl":"10.21037/tcr-2024-2555","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of second-line chemotherapy with pemetrexed or docetaxel was evaluated in phase III clinical trials only after prior treatment with a platinum doublet in non-small cell lung cancer. The effectiveness of second-line chemotherapy after previous chemotherapy and immunotherapy is not well known. The effectiveness of third-line chemotherapy is not practically proven in this sense. The aim of this retrospective study was therefore to assess the effectiveness of second- and third-line chemotherapy in patients pretreated with chemotherapy with platinum doublet and immunotherapy based on retrospective data.</p><p><strong>Methods: </strong>Patients from the Czech Lung Cancer Focus (LUCAS) lung cancer registry who were pretreated with chemotherapy and immunotherapy were evaluated. Time on treatment (ToT) and overall survival (OS) with second- and third-line chemotherapy were evaluated using Kaplan-Meier method.</p><p><strong>Results: </strong>One hundred and fourteen patients treated with second-line chemotherapy were evaluated. Their ToT reached a median of 2.9 [95% confidence interval (CI): 2.4-4.7] months and OS a median of 7.2 (95% CI: 6.1-11.2) months. Twenty-two patients treated with third-line chemotherapy were evaluated. Their ToT reached a median of 5.1 (95% CI: 1.4-NA) months and OS a median of 13.8 (95% CI: 6.1-NA) months.</p><p><strong>Conclusions: </strong>The efficacy of second-line chemotherapy in our group of patients (pretreated with chemotherapy and immunotherapy) was comparable with registration studies for second-line chemotherapy. In a selected population, even third-line chemotherapy can be effective.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4348-4356"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence, risk factors, and survival of acute myeloid leukemia secondary to chronic myelomonocytic leukemia: a population-based study.","authors":"Wenshuai Zheng, Yanchao Liang, Jijia Zheng, Zirui Zhu, Zongze Wu, Lixun Guan","doi":"10.21037/tcr-2025-373","DOIUrl":"10.21037/tcr-2025-373","url":null,"abstract":"<p><strong>Background: </strong>Chronic myelomonocytic leukemia (CMML) is a heterogeneous myeloid malignancy, characterized by sustained peripheral blood monocytosis and an inherent risk of secondary acute myeloid leukemia (s-AML). This study aimed to determine the incidence, risk factors, and survival of AML secondary to CMML.</p><p><strong>Methods: </strong>We conducted this retrospective analysis based on the Surveillance, Epidemiology, and End Results (SEER) database.</p><p><strong>Results: </strong>We identified 3,218 patients with primary CMML. After a median follow-up time of 23 months, 291 patients developed s-AML and most of them occurred in the first year of CMML diagnosis, with cumulative incidence of 10.8%. In competing risk analysis, risk factors for s-AML were younger age and exposure to chemotherapy at CMML diagnosis. The post-progression survival (PPS) of s-AML was dismal with a median survival of 4 months (1-, 3-, and 5-year PPS of 26.6%, 9.6%, and 7.1%, respectively), while younger age and exposure to chemotherapy at s-AML development were protective factors for PPS. Considering CMML, s-AML development, older age, and exposure to chemotherapy at CMML diagnosis were risk factors for overall survival (OS). In addition, being married, higher income, and non-Hispanic White were important protective factors for OS of CMML.</p><p><strong>Conclusions: </strong>The risk of s-AML among CMML was high and the PPS was poor. Age and exposure to chemotherapy at CMML diagnosis were associated with the high risk of s-AML and the poor survival of s-AML. In addition to clinical factors, demographic factors, including marital status, economic level, and race/ethnicity, should also be included when assessing the CMML survival.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"3930-3942"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-490-5p inhibits the progression of osteosarcoma by targeting HDAC2.","authors":"Huiqun Jiang, Jiahao Xia, Yuan Tao, Yu Zhang","doi":"10.21037/tcr-2024-2217","DOIUrl":"10.21037/tcr-2024-2217","url":null,"abstract":"<p><strong>Background: </strong>Osteosarcoma (OS) is the most prevalent malignant bone tumor and has a particularly unfavorable prognosis. Although miR-490-5p is regarded as an established diagnostic and predictive marker for human cancers, the role of miR-490-5p in OS remains presently unclear. The aim of this study was to clarify the function of miR-490-5p in OS.</p><p><strong>Methods: </strong>Bioinformatics analysis of OS cells was performed to identify differentially expressed microRNAs (miRNAs, miRs). Then, the expression profiles of miR-490-5p in various OS cells were determined by real-time polymerase chain reaction analysis. The roles of miR-490-5p in OS cells were assessed through <i>in vitro</i> cytological experiments. Bioinformatics methods were used to predict target genes. The relationship between miR-490-5p and HDAC2 was demonstrated by a dual-luciferase reporter gene assay.</p><p><strong>Results: </strong>Expression of miR-490-5p was relatively decreased in OS cells. Overexpression of miR-490-5p inhibited proliferation and metastasis of OS cells. Moreover, miR-490-5p was found to negatively regulate HDAC2 as a downstream target gene. Recovery experiments confirmed that HDAC2 overexpression rescued the inhibitory effect on OS progression by overexpression of miR-490-5p.</p><p><strong>Conclusions: </strong>MiR-490-5p directly regulated HDAC2 expression, thereby modulating the growth and metastatic capacity of OS cells. The miR-490-5p/HDAC2 axis could serve as a promising therapeutic target for OS.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4357-4368"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}